These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 32900459)

  • 41. Plasminogen activation and thrombolysis for ischemic stroke.
    Medcalf RL; Davis SM
    Int J Stroke; 2012 Jul; 7(5):419-25. PubMed ID: 22463085
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combined lysis of thrombus with ultrasound and systemic tissue plasminogen activator for emergent revascularization in acute ischemic stroke (CLOTBUST-ER): design and methodology of a multinational phase 3 trial.
    Schellinger PD; Alexandrov AV; Barreto AD; Demchuk AM; Tsivgoulis G; Kohrmann M; Alleman J; Howard V; Howard G; Alexandrov AW; Brandt G; Molina CA;
    Int J Stroke; 2015 Oct; 10(7):1141-8. PubMed ID: 26120902
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In acute ischemic stroke patients with smoking incidence, are more women than men more likely to be included or excluded from thrombolysis therapy?
    Rotimi OR; Ajani IF; Penwell A; Lari S; Walker B; Nathaniel TI
    Womens Health (Lond); 2020; 16():1745506520922760. PubMed ID: 32459136
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modulation by the Noble Gas Helium of Tissue Plasminogen Activator: Effects in a Rat Model of Thromboembolic Stroke.
    Haelewyn B; David HN; Blatteau JE; Vallée N; Meckler C; Risso JJ; Abraini JH
    Crit Care Med; 2016 Jun; 44(6):e383-9. PubMed ID: 26646461
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Administration of intravenous tissue plasminogen activator in a pediatric patient with acute ischemic stroke.
    Shuayto MI; Lopez JI; Greiner F
    J Child Neurol; 2006 Jul; 21(7):604-6. PubMed ID: 16970853
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of Acute Ischemic Stroke.
    Siket MS
    Emerg Med Clin North Am; 2016 Nov; 34(4):861-882. PubMed ID: 27741992
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator.
    Betts KA; Hurley D; Song J; Sajeev G; Guo J; Du EX; Paschoalin M; Wu EQ
    J Stroke Cerebrovasc Dis; 2017 Sep; 26(9):1996-2003. PubMed ID: 28689999
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ten-Year Evaluation of the TOYOTA Prehospital Stroke Scale for Tissue Plasminogen Activator Intravenous Therapy in the Real World.
    Suzuki J; Nakai N; Kondo N; Tsuji H; Inagaki R; Furukawa S; Iwata M; Nishida S; Ito Y
    Cerebrovasc Dis; 2018; 46(3-4):184-192. PubMed ID: 30384371
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Empirical characteristics of litigation involving tissue plasminogen activator and ischemic stroke.
    Liang BA; Zivin JA
    Ann Emerg Med; 2008 Aug; 52(2):160-4. PubMed ID: 18313798
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Letter by Shah Regarding Article, "Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke)".
    Shah NH
    Stroke; 2017 Sep; 48(9):e258. PubMed ID: 28754831
    [No Abstract]   [Full Text] [Related]  

  • 51. Cutting Edge Acute Ischemic Stroke Management.
    Urdaneta AE; Bhalla P
    Emerg Med Clin North Am; 2019 Aug; 37(3):365-379. PubMed ID: 31262409
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of intravenous tissue plasminogen activator and hospital costs for patients with acute ischaemic stroke aged 18-64 years in the USA.
    Joo H; Wang G; George MG
    Stroke Vasc Neurol; 2016 Mar; 1(1):8-15. PubMed ID: 27547449
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thrombolysis beyond 4.5 h in Acute Ischemic Stroke.
    Etherton MR; Gadhia RR; Schwamm LH
    Curr Neurol Neurosci Rep; 2020 Jun; 20(8):35. PubMed ID: 32607627
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tissue plasminogen activator for ischemic stroke: unintended consequences.
    J Emerg Nurs; 2003 Apr; 29(2):96-7. PubMed ID: 12660689
    [No Abstract]   [Full Text] [Related]  

  • 55. Cost-Effectiveness of Intra-Arterial Treatment as an Adjunct to Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke.
    Leppert MH; Campbell JD; Simpson JR; Burke JF
    Stroke; 2015 Jul; 46(7):1870-6. PubMed ID: 26012639
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Large ischemic lesions on diffusion-weighted imaging done before intravenous tissue plasminogen activator thrombolysis predicts a poor outcome in patients with acute stroke.
    Kimura K; Iguchi Y; Shibazaki K; Terasawa Y; Inoue T; Uemura J; Aoki J
    Stroke; 2008 Aug; 39(8):2388-91. PubMed ID: 18535272
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Response by Barreto and Grotta to Letter Regarding Article, "Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke)".
    Barreto AD; Grotta JC
    Stroke; 2017 Sep; 48(9):e259. PubMed ID: 28754829
    [No Abstract]   [Full Text] [Related]  

  • 58. Response to letter regarding article, "standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses".
    Liao X; Wang Y; Wang Y
    Stroke; 2014 Dec; 45(12):e304. PubMed ID: 25342031
    [No Abstract]   [Full Text] [Related]  

  • 59. Worldwide reported use of IV tissue plasminogen activator for acute ischemic stroke.
    Berkowitz AL; Mittal MK; McLane HC; Shen GC; Muralidharan R; Lyons JL; Shinohara RT; Shuaib A; Mateen FJ
    Int J Stroke; 2014 Apr; 9(3):349-55. PubMed ID: 24207029
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Authors' reply.
    Soto-Cámara R; González-Santos J; González-Bernal J; Trejo-Gabriel-Galán JM
    Emergencias; 2020 Nov; 32(6):448-449. PubMed ID: 33275376
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.